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Primary graft failure in recipients of cardiac allografts is alife-threatening condition that demands implantation of anextracorporeal membrane oxygenator (ECMO) to weanthese patients from cardiopulmonary bypass (CPB). In this
report, we are presenting our recent experience with 6 patients who
underwent ECMO insertion after primary allograft failure. We were
able to wean 5 patients from ECMO. One patient died on ECMO
support after retransplantation. Two other patients died of sepsis-
induced multiple organ failure after successful weaning. This series
suggests that ECMO implantation is feasible in overcoming prima-
ry organ failure.
No consensus has been reached on the indications for mechan-
ical support after heart transplantation in adults having intraopera-
tive graft failure. The literature on extracorporeal life support and
primary graft failure is scarce, and information and guidelines per-
taining to this life-threatening condition are limited.1,2 Right and
left ventricular assist devices have been of moderate benefit in this
critical clinical setting.3 ECMO support is used in patients with
postcardiotomy shock syndrome4 or acute respiratory distress syn-
drome.5 ECMO is currently used in our institution to avoid reper-
fusion edema after lung transplantation and in patients with prima-
ry pulmonary hypertension. In this article, we are describing our
recent experience in patients with primary allograft failure treated
by implantation of an ECMO.
Methods and Results
ECMO characteristics and technique and outcome. The
ECMO adult circuit consisted of a Medtronic console 450 or 550
and a Medtronic Bio-Cal Blood Temperature Control Module
(Medtronic, Inc, Minneapolis, Minn). The oxygenator is a hollow-
fiber membrane oxygenator with an integrated heat exchanger. The
cannulas are Medtronic Bio-Medicus (Eden Prairie, Minn) cannu-
las that are wirewound to prevent kinking and are radiopaque. The
setup of the ECMO involved cutdown cannulation of the femoral
vein and artery. Drainage was accomplished from the right atrium
via the femoral vein, whereas the oxygenated blood was reinfused
through the femoral artery. The distal femoral artery was perfused
through the additional cannula.
Acute graft failure developed in 6 adult patients after orthotopic
heart transplantation. These patients underwent extracorporeal life
support (ECMO, Medtronic) to be weaned from CPB (Table 1) The
charts of this patient cohort were reviewed. Three patients had
dilatative cardiomyopathy, 2 patients had ischemic cardiomyopa-
thy, and 1 patient had malignant recurrent ventricular arrhythmia
(male/female ratio 5:1, mean age 46 ± 17 years, range 28-60 years).
Four patients were supported with ECMO for intraoperative biven-
tricular failure, and 2 recipients had right ventricular dysfunction
caused by pulmonary hypertension refractory to alprostadil
(prostaglandin E1)/nitric oxide therapy. The hemodynamic data,
donor age, and total ischemic time are listed in Table 2.
Comment
The prognosis of patients with end-stage cardiomyopathy is poor,
and heart allograft transplantation is the standard modality with
documented long-term results.6 Allograft malfunction with subse-
quent nonweaning from CPB can be a result of a multifactorial gen-
esis, including effects of ischemia, preservation injury, denervation,
acute humoral and cellular rejection, and surgical manipulation.
Additionally, extracorporeal circulation is associated with a release of
vasoactive substances.7,8 Increased vascular resistance is associated
with a life-threatening risk of right ventricular failure after heart
transplantation and is a widely established predictor of mortality in
heart transplantation.9 This in turn results in an acute increase in right
ventricular afterload for the allograft and may lead to right ventricu-
lar failure; left ventricular failure is deemed to be caused by preser-
vation injury. As a result of these conditions, the patient cannot be
weaned from CPB with conservative therapy. Inotropic drugs are
given to increase ventricular contractility and heart rate. More impor-
tant, a reduction of pulmonary vascular resistance may improve ven-
tricular performance and prevent right ventricular failure after heart
transplantation. Alprostadil (prostaglandin E1) and nitric oxide have
been shown to be potent but nonselective pulmonary vasodilators
with the potential for reduced pulmonary afterload. However, despite
maximal drug treatment, some allograft recipients may require
mechanical support to be weaned from CPB because of severe
myocardial injury and pulmonary hypertension. Since installation of
right or left ventricular assist devices is a viable option in this sce-
nario, the cost effectiveness and more invasiveness of this procedure
may limit applicability. In our institution, after reaching threshold
levels of inotropic drug use (norepinephrine 0.2 γ, suprarenin 0.3 γ
[1 γ = µg · kg–1 · min–1]), we are opting for insertion of ECMOs via
venoarterial access because this is a less invasive procedure. 
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Owing to the scarcity of literature relating to this therapeutic
modality in adults, various aspects deserve comment. First, patient
referral from the operating theater was possible in all patients.
Second, weaning from ECMO was possible in 82.3%, within a
mean period of 71.4 ± 41.9 hours. Because of the circulatory sup-
port, right and left ventricular distention was reduced and recovery
of allograft heart function was made possible. Patients were
weaned from ECMO in a stepwise fashion with echocardiograph-
ic and hemodynamic monitoring. Third, as a result of immunosup-
pressive treatment, 2 patients died of multiorgan failure after veri-
fied blood-borne sepsis. This warrants aggressive prophylactic
antibiotic and antimycotic treatment. Our single-center experience
suggests that ECMO is a feasible and cost-effective mechanical
support to overcome primary allograft dysfunction.
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TABLE 1. Six patients with acute graft failure after orthotopic heart transplantation who required ECMO to be weaned from
CPB
Patient (sex, age [y]) Diagnosis Indications for ECMO Duration of ECMO (h) Weaning Survival
1 (M, 60) ICMP Biventricular failure 49 h (RHTX) No No
2 (F, 47) HCMP RVF 94 h Yes No, POD 18, urosepsis
3 (M, 57) DCMP RVF 120 h Yes Yes
4 (M, 57) ICMP Biventricular failure 125 h Yes No, sepsis
5 (M, 28) DCMP Biventricular failure 32 h Yes Yes
6 (M, 34) DCMP, malignant arrhythmia Biventricular failure 38 h Yes Yes
ICMP, Ischemic cardiomyopathy; HCMP, hypertrophic cardiomyopathy; DCMP, dilatative cardiomyopathy; RVF, right ventricular failure; RHTX, retransplan-
tation; POD, postoperative day.
TABLE 2. Hemodynamic data, donor age, and total ischemic time
Patient PAP(s/d/m) PVR (WU) LVEF (%) Donor age Total ischemic time (min)
1 56/36/43 5.3 10 59 M 207 
28 F 230
2 64/29/42 3.1 30 28 F 201
3 53/28/38 4.3 12 43 M 150
4 56/32/40 3 30 35 M 180
5 36/18/25 1 32 25 F 225
6 49/24/35 0.2 40 52 M 249
PAP, Pulmonary artery pressure; s/d/m, systolic, diastolic, mean; PVR, pulmonary vascular resistance; WU, Wood units; LVEF, left ventricular ejection fraction.
